• Independent Data Monitoring Committee recommends discontinuation of TACTI-004 Phase III trial in first line NSCLC following futility analysis
• Immutep to halt enrolment and wind down the study
• Company to conduct comprehensive review of data and determine next steps

Immutep Limited announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol. Based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility. In response to the IDMC's recommendation, enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations. Immutep's CEO, Marc Voigt, expressed disappointment and surprise with the outcome, given efti's performance in other clinical trials. The Company will conduct a comprehensive review of the available data to better understand the results and determine the appropriate next steps for the program. Immutep remains focused on advancing its pipeline of innovative therapies including efti.